Scrip Podcasts https://insights.citeline.com/scrip/ en All rights reserved Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. https://megaphone.imgix.net/podcasts/bc226ce2-31a8-11f1-b5b6-abbed618de63/image/10e04a5203a093189d459554154a2faf.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Scrip Podcasts https://insights.citeline.com/scrip/ episodic Norstella Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. Scrip delivers expert-driven audio insight on biopharma — from R&D, commercial strategy and deal activity to coverage of major industry events. Every Monday, Ian Haydock presents Quick Listen: Five Must-Know Things, a weekly roundup of top industry stories. Joseph Haas hosts a quarterly deep-dive into dealmaking with guests from leading companies, law firms and investment firms. Visit https://insights.citeline.com/scrip to sign up. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

]]> Norstella webpubs@citeline.com Assessing the current dealmaking environment for psychedelic medicine. Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration. Fri, 18 Sep 2026 14:52:00 -0000 full Norstella Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration. Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

]]> 1181 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Sept. 14, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；以及中国企业在全球范围内的III期临床试验动态。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com Mon, 14 Sep 2026 02:26:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；以及中国企业在全球范围内的III期临床试验动态。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年9月11日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 本期内容包括：近期III期试验失败后，心血管领域研发的下一步动向；全球销量前十的药物中有九款在第二季度实现连续增长；阿斯利康的首创性慢性阻塞性肺病（COPD）药物在III期试验中表现优于Dupixent；Renexxion联合创始人解析纳罗那普利为何能在胃轻瘫治疗中取得成功；以及中国企业在全球范围内的III期临床试验动态。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: podcasts@norstella.com

]]> 1198 no Scrip's Five Must-Know Things - Sept, 14, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-performs Dupixent in Phase III trial; Renexxion’s co-founder explains why naronapride can succeed in gastroparesis; and Chinese companies expand global Phase III activity.  Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Mon, 14 Sep 2026 02:26:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-performs Dupixent in Phase III trial; Renexxion’s co-founder explains why naronapride can succeed in gastroparesis; and Chinese companies expand global Phase III activity.  Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com.

Audio roundup of selected biopharma industry content from Scrip over the business week ended Sept. 11, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—what’s next in cardiovascular R&D following recent Phase III failures; sequential gains for nine of the world’s 10 best-selling drugs in Q2; AstraZeneca’s first-in-class COPD contender out-performs Dupixent in Phase III trial; Renexxion’s co-founder explains why naronapride can succeed in gastroparesis; and Chinese companies expand global Phase III activity. 

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-G5UM7ATTY5E3DAD6X7NW2OI4EA/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on podcasts@norstella.com.

]]> 1111 no 中国药企2026年全球III期临床试验巡礼——从“单点突破”到“常态化出海” (Chinese-language podcast, Sept. 11, 2026) 根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。 Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-phase-iii-trials-with-us-sites-so-far-in-2026-7ZFDORUPSJGBDOCM2MFPDOPNT4/   Fri, 11 Sep 2026 06:24:00 -0000 full Norstella 根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。 Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-phase-iii-trials-with-us-sites-so-far-in-2026-7ZFDORUPSJGBDOCM2MFPDOPNT4/   根据Citeline旗下Scrip在2026年9月4日发布的最新统计，截至今年8月底，已经有六个由中国药企作为唯一申办方且在美国招募患者的全球III期临床试验启动。这个节奏已经追平了2025年全年的总量。今天我们就把这六个临床试验挨个拆开来看，再聊聊这背后代表的行业信号。

Story link: https://insights.citeline.com/scrip/r-and-d/clinical-trials/chinese-firms-start-six-global-phase-iii-trials-with-us-sites-so-far-in-2026-7ZFDORUPSJGBDOCM2MFPDOPNT4/

 

]]> 671 no Advancing CNS Drug Development Through AI, New Approach Methodologies and Regulatory Innovation Tue, 01 Sep 2026 10:00:00 -0000 full Norstella 802 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 31, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com Mon, 31 Aug 2026 02:30:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月28日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 礼来研究显示Zepbound带来的成本节约可能超过其售价；罗氏达成最高23亿美元的韩美制药“肌肉保护型”减肥药交易；Revolution的Rasonque获美国批准用于治疗胰腺癌，Jazz的Ziihera获批用于治疗胃食管癌；以及梯瓦和维亚特里斯从仿制药转向创新药。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: podcasts@norstella.com


]]> 1182 no Scrip's Five Must-Know Things - Aug. 31, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivoting from generics to novel drugs. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Mon, 31 Aug 2026 02:06:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivoting from generics to novel drugs. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 28, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivoting from generics to novel drugs.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DSLQFWB2YVHD5J6OT3FF3OUTAY/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on podcasts@norstella.com.

]]> 1124 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 24, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/ Pipeline to Patient Productivity Index: https://www.norstella.com/p3i/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com Mon, 24 Aug 2026 03:25:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/ Pipeline to Patient Productivity Index: https://www.norstella.com/p3i/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Feedback: podcasts@norstella.com 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月21日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: Moderna的mRNA候选药物在黑色素瘤治疗方面取得突破；Enhertu在肺癌治疗方面取得胜利；衡量行业研发生产力；Enveda的GLP-1后继候选药物；以及中国崛起的背后因素。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/

Pipeline to Patient Productivity Index: https://www.norstella.com/p3i/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

Feedback: podcasts@norstella.com

]]> 1055 no Scrip's Five Must-Know Things - Aug. 24, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 21, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/ Link to Pipeline to Patient Productivity Index report: https://www.norstella.com/p3i/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Mon, 24 Aug 2026 02:51:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 21, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/ Link to Pipeline to Patient Productivity Index report: https://www.norstella.com/p3i/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 21, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ATTKRKGOMNAV3J6PRL2PAKBJKU/

Link to Pipeline to Patient Productivity Index report: https://www.norstella.com/p3i/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on podcasts@norstella.com.

]]> 1032 no Scrip Trailer Wed, 19 Aug 2026 17:34:00 -0000 trailer Norstella 102 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 17, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月14日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 全球特发性肺纤维化（IPF）研发管线概览；武田制药的嗜睡症药物获美国批准；Arrowhead公司探讨严重高甘油三酯血症治疗方案的差异化；SMID公司第二季度进展；以及Attruby在伴有心肌病变的转甲状腺素蛋白介导的淀粉样变性中的定位。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-X73TT3G6OVE7VPYRLSKYQRY5PY/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Mon, 17 Aug 2026 02:15:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月14日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 全球特发性肺纤维化（IPF）研发管线概览；武田制药的嗜睡症药物获美国批准；Arrowhead公司探讨严重高甘油三酯血症治疗方案的差异化；SMID公司第二季度进展；以及Attruby在伴有心肌病变的转甲状腺素蛋白介导的淀粉样变性中的定位。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-X73TT3G6OVE7VPYRLSKYQRY5PY/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月14日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 全球特发性肺纤维化（IPF）研发管线概览；武田制药的嗜睡症药物获美国批准；Arrowhead公司探讨严重高甘油三酯血症治疗方案的差异化；SMID公司第二季度进展；以及Attruby在伴有心肌病变的转甲状腺素蛋白介导的淀粉样变性中的定位。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-X73TT3G6OVE7VPYRLSKYQRY5PY/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。


]]> 1180 no Scrip's Five Must-Know Things - Aug. 17, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 14, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-X73TT3G6OVE7VPYRLSKYQRY5PY/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Mon, 17 Aug 2026 02:04:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 14, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-X73TT3G6OVE7VPYRLSKYQRY5PY/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Contact us on podcasts@norstella.com. Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 14, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—a look at the global IPF pipeline; US approval for Takeda's narcolepsy drug; Arrowhead talks differentiation in severe hypertriglyceridemia; SMID Q2 developments; and Attruby positioning in transthyretin-mediated amyloidosis with cardiomyopathy.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-X73TT3G6OVE7VPYRLSKYQRY5PY/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

Contact us on podcasts@norstella.com.

]]> 1063 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 10, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月7日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德考虑进行补充性收购；拜耳抨击德国定价政策；尽管Foundayo表现不佳，礼来股价仍大幅上涨；欧洲生物技术企业力求实现跨越式发展；以及对阿斯利康与百时美施贵宝在亚太地区潜在合并的展望。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AGQ4WMY4Y5BBFP7F67BNWXIPM4/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Mon, 10 Aug 2026 03:22:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月7日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德考虑进行补充性收购；拜耳抨击德国定价政策；尽管Foundayo表现不佳，礼来股价仍大幅上涨；欧洲生物技术企业力求实现跨越式发展；以及对阿斯利康与百时美施贵宝在亚太地区潜在合并的展望。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AGQ4WMY4Y5BBFP7F67BNWXIPM4/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年8月7日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 诺和诺德考虑进行补充性收购；拜耳抨击德国定价政策；尽管Foundayo表现不佳，礼来股价仍大幅上涨；欧洲生物技术企业力求实现跨越式发展；以及对阿斯利康与百时美施贵宝在亚太地区潜在合并的展望。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AGQ4WMY4Y5BBFP7F67BNWXIPM4/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

]]> 1003 no Scrip's Five Must-Know Things - Aug. 10, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 7, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AGQ4WMY4Y5BBFP7F67BNWXIPM4/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Mon, 10 Aug 2026 03:00:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 7, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AGQ4WMY4Y5BBFP7F67BNWXIPM4/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Audio roundup of selected biopharma industry content from Scrip over the business week ended Aug. 7, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time—Novo Nordisk weighs bolt-on deals; Bayer slams Germany pricing; Lilly soars despite Foundayo struggles; European biotech wants to leapfrog; and a look at the potential AstraZeneca/BMS combination in APAC.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AGQ4WMY4Y5BBFP7F67BNWXIPM4/

This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

]]> 1020 no Podcast: China's Evolving Role in Global Clinical Development China has become an increasingly important part of global clinical development, with sponsors considering the region earlier than ever before as part of their broader development strategies. In this episode, Meredith Landry, Managing Editor of Citeline's Custom Content, speaks with Catherine Xu, Senior Operations Manager at Novotech, about the factors reshaping China's role in global clinical development. Drawing on her extensive experience supporting international clinical programmes, Catherine shares insights into the changing perceptions of China, the evolving regulatory landscape, and what sponsors should consider when planning global development strategies. In this conversation, they explore: • Why more sponsors are rethinking China's role in global clinical development • The opportunities and misconceptions shaping today's development strategies • What sponsors should consider when incorporating China into global programmes • How China's role in global clinical development could evolve over the coming years Tue, 04 Aug 2026 09:14:00 -0000 full Norstella China has become an increasingly important part of global clinical development, with sponsors considering the region earlier than ever before as part of their broader development strategies. In this episode, Meredith Landry, Managing Editor of Citeline's Custom Content, speaks with Catherine Xu, Senior Operations Manager at Novotech, about the factors reshaping China's role in global clinical development. Drawing on her extensive experience supporting international clinical programmes, Catherine shares insights into the changing perceptions of China, the evolving regulatory landscape, and what sponsors should consider when planning global development strategies. In this conversation, they explore: • Why more sponsors are rethinking China's role in global clinical development • The opportunities and misconceptions shaping today's development strategies • What sponsors should consider when incorporating China into global programmes • How China's role in global clinical development could evolve over the coming years China has become an increasingly important part of global clinical development, with sponsors considering the region earlier than ever before as part of their broader development strategies.

In this episode, Meredith Landry, Managing Editor of Citeline's Custom Content, speaks with Catherine Xu, Senior Operations Manager at Novotech, about the factors reshaping China's role in global clinical development. Drawing on her extensive experience supporting international clinical programmes, Catherine shares insights into the changing perceptions of China, the evolving regulatory landscape, and what sponsors should consider when planning global development strategies.

In this conversation, they explore:

• Why more sponsors are rethinking China's role in global clinical development

• The opportunities and misconceptions shaping today's development strategies

• What sponsors should consider when incorporating China into global programmes

• How China's role in global clinical development could evolve over the coming years

]]> 1059 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) Aug. 3, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月31日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 阿斯利康收紧人工智能支出；Argenx的产品管线聚焦产品开发；葛兰素史克在推进III期临床试验计划的同时削减成本；赛诺菲对产品管线进行重新评估；以及中国业务新公司2.0版。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AN2QWPVGAZGCND565XO3QDMBBM/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Mon, 03 Aug 2026 02:41:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月31日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 阿斯利康收紧人工智能支出；Argenx的产品管线聚焦产品开发；葛兰素史克在推进III期临床试验计划的同时削减成本；赛诺菲对产品管线进行重新评估；以及中国业务新公司2.0版。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AN2QWPVGAZGCND565XO3QDMBBM/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月31日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 阿斯利康收紧人工智能支出；Argenx的产品管线聚焦产品开发；葛兰素史克在推进III期临床试验计划的同时削减成本；赛诺菲对产品管线进行重新评估；以及中国业务新公司2.0版。

Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AN2QWPVGAZGCND565XO3QDMBBM/


向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

]]> 1076 no Scrip's Five Must-Know Things - Aug. 3, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended July 31, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AN2QWPVGAZGCND565XO3QDMBBM/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Mon, 03 Aug 2026 01:39:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 31, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AN2QWPVGAZGCND565XO3QDMBBM/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 31, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.


This time—AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets.


Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-AN2QWPVGAZGCND565XO3QDMBBM/


This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

]]> 971 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) July 27, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德在肥胖症治疗领域起诉礼来；特朗普针对仿制药采取新的关税措施；诺华CEO称赞日本、抨击德国的定价政策；制药行业会迎来“稀土时刻”吗？；以及欧洲生物技术行业正处于十字路口。 Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2BIDCWDH5BAVLJ2QXPT6EL5U44/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Mon, 27 Jul 2026 02:40:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 诺和诺德在肥胖症治疗领域起诉礼来；特朗普针对仿制药采取新的关税措施；诺华CEO称赞日本、抨击德国的定价政策；制药行业会迎来“稀土时刻”吗？；以及欧洲生物技术行业正处于十字路口。 Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2BIDCWDH5BAVLJ2QXPT6EL5U44/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 诺和诺德在肥胖症治疗领域起诉礼来；特朗普针对仿制药采取新的关税措施；诺华CEO称赞日本、抨击德国的定价政策；制药行业会迎来“稀土时刻”吗？；以及欧洲生物技术行业正处于十字路口。


Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2BIDCWDH5BAVLJ2QXPT6EL5U44/


向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

]]> 1064 no Scrip's Five Must-Know Things - July 27, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended July 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.  Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2BIDCWDH5BAVLJ2QXPT6EL5U44/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Mon, 27 Jul 2026 01:50:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.  Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2BIDCWDH5BAVLJ2QXPT6EL5U44/ This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.


This time—Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads. 


Story/video links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2BIDCWDH5BAVLJ2QXPT6EL5U44/


This and all our other podcasts are available on the new Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

]]> 963 no European Biotech At A Crossroads: How Can It Stay Competitive? Video Podcast This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions. Wed, 22 Jul 2026 15:15:00 -0000 full Norstella This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions. This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions.

]]> 3063 no Scrip's Five Must-Know Things - July 21, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended July 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.  Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-OBTX6Q73CNCKVDV6GDYG4YM7SI/ This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Tue, 21 Jul 2026 05:41:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time—J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.  Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-OBTX6Q73CNCKVDV6GDYG4YM7SI/ This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 17, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.


This time—J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer. 

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-OBTX6Q73CNCKVDV6GDYG4YM7SI/


This and all our other podcasts are available on the Scrip channel on Apple Podcasts, and Spotify Podcasts and on TuneIn.

]]> 983 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) July 21, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 强生上调业绩预期；吉利德的收购策略；拜耳拆分传闻；百健的阿尔茨海默病研究结果；以及对礼来血液检测先驱的专访。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Tue, 21 Jul 2026 05:39:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 强生上调业绩预期；吉利德的收购策略；拜耳拆分传闻；百健的阿尔茨海默病研究结果；以及对礼来血液检测先驱的专访。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 强生上调业绩预期；吉利德的收购策略；拜耳拆分传闻；百健的阿尔茨海默病研究结果；以及对礼来血液检测先驱的专访。


向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。



]]> 1080 no Alzheimer's AAIC Video Interview: Denali Therapeutics Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development. Mon, 20 Jul 2026 13:42:00 -0000 full Norstella Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development. Denali CEO Ryan Watts talks about the company's TransportVehicle platform and how it can open up delivery of a wide range of drug cargoes into the brain. Its first approved therapy is Avlayah for Hunter Syndrome, with tau and beta-amyloid targeting assets for Alzheimer's in development.

]]> 399 no Eisai Video Interview AT AAIC Alzheimer's Conference, July 15 Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug. Fri, 17 Jul 2026 12:54:00 -0000 full Norstella Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug. Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.

]]> 752 no Scrip Deals Podcast, July 2026, with Dr. Bruce Leuchter On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026. Thu, 16 Jul 2026 17:54:00 -0000 full Norstella On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026. On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on 2023-2025.. Leuchter offered some insights on why this might be. Haas and Leuchter also discussed M&A activity during the just-ended second quarter of 2026.

]]> 2084 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) July 13, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Tue, 14 Jul 2026 02:05:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: Vertex收购Crinetics；阿斯利康III期试验失败；强生公司的并购重点；伊普森（Ipsen）的“寻宝”之旅；以及Dyne首席执行官谈战略。


向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。




]]> 1098 no Scrip's Five Must-Know Things - July 13, 2026 Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RR3G5D6X5NEANCNJ2DVQ7OCAS4/ A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Tue, 14 Jul 2026 01:53:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RR3G5D6X5NEANCNJ2DVQ7OCAS4/ A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time–Vertex's Crinetics deal; AstraZeneca's Phase III fail; J&J's deal focus; Ipsen's search for diamonds; and Dyne's CEO on strategy.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RR3G5D6X5NEANCNJ2DVQ7OCAS4/

A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes.


]]> 971 no Scrip's Five Must-Know Things - July 6, 2026 https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/ Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/   A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Mon, 06 Jul 2026 03:35:00 -0000 full Norstella Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/   A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes. Audio roundup of selected biopharma industry content from Scrip over the business week ended July 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time–later stage assets help fundraising; dealmaking surges this year; Amgen’s approach to AI; Takeda’s AI strategy; and Anthropic launches Claude Science.

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/

 

A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple Podcasts.​ ​Be sure to subscribe to get all episodes.


]]> 982 no Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) July 6, 2026 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 Mon, 06 Jul 2026 00:36:00 -0000 full Norstella 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。 本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年7月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 后期阶段资产助力融资；今年并购活动激增；安进（Amgen）对 AI的策略；武田（Takeda）的AI战略；以及Anthropic推出Claude Science。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-WGWUOFC7J5BJ5IMWNX5QJMOWNU/

向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。

]]> 1077 no Podcast: Europe’s Evolving Role in Global Clinical Trials As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global development programs amid shifting geopolitical, regulatory, and operational dynamics. Mon, 18 May 2026 11:09:00 -0000 full Norstella As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials. In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global development programs amid shifting geopolitical, regulatory, and operational dynamics. As global clinical development strategies evolve, Europe is emerging as a critical hub for scientific innovation, operational agility, and patient recruitment — reshaping its role in the future of clinical trials.

In this episode, Scott Davis, Vice President of Clinical Services at Novotech, joins Andrew Warmington from Citeline to explore how sponsors are rethinking Europe’s place in global development programs amid shifting geopolitical, regulatory, and operational dynamics.

]]> 625 no Scrip Deals Podcast: An Interview With Jeremy Levin Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science. Thu, 14 May 2026 02:43:00 -0000 full Norstella Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science. Ovid Therapeutics Chairman Jeremy Levin talks with Scrip about how the US should view its biotech sector as a strategic national asset and urges the venture capital sector to place more emphasis on supporting early and innovative science.

]]> 2779 no The Scrip Awards Podcast - Call For Entries 2026, New AI Category, Triana Interview Tue, 12 May 2026 14:38:00 -0000 full Norstella 1500 no